Advocacy intelligence hub — real-time data for patient organizations
MYCAPSSA (formerly Octreolin): FDA approved
Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
MYCAPSSA (formerly Octreolin)
Chiesi USA, Inc.
MYCAPSSA (formerly Octreolin)
(octreotide (oral))Orphan drugChiesi USA, Inc.
Kateřina Sobotková
University Hospital Brno and Faculty of Medicine
Milan Urík
University Hospital Brno and Faculty of Medicine
Klára Perce
University Hospital Brno and Faculty of Medicine
Barbora Petrová
University Hospital Brno and Faculty of Medicine
Soňa Šikolová
University Hospital Brno and Faculty of Medicine
Michal Bartoš
University Hospital Brno and Faculty of Medicine